

Technology Advisory Committee D Interests Register

Topic [ID4032]

Publication Date: TBC

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|-----------------------|----------------|-----------------------|---|-------------------------------------|---|
| Jefferson Courtney | Patient expert | Direct - Professional | <p>James is an employee of the nominating organisation (Haemophilia Society).</p> <p>Both patient experts (James Courtney and Ross Bennett) are nominated by the Haemophilia Society who receives funding from companies involved in the development, manufacture, marketing and distribution of treatments for haemophilia and other bleeding disorders. The companies, total amounts and projects funded for the financial year 22/23 are listed below:</p> <ul style="list-style-type: none"> • CSL Behring £60,000 – Communications, Core Funding • LFB £10,000 – Women's Project • Novo Nordisk £16,000 – Conference Attendance, Member Magazine, Information Days • Octapharma £10,000 – Women's Project • Pfizer £20,000 – Youth Ambassador Project, Publications | <p>09/04/2024</p> <p>06/06/2024</p> | It was agreed that Jefferson's declaration would not prevent him from providing expert advice to the committee. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|-----------------|--------------------|---|-------------------|--|
| | | | <ul style="list-style-type: none"> Roche/Chugai £15,000 – Transition Project, Newly Diagnosed Weekends Sobi £25,000 – Publications, Conference Attendance, Information Days Takeda £19,000 Women's Project, Publications | | |
| Dr Dalia Khan | Clinical expert | Direct – Financial | Dr Khan has received funding from Roche to go to conferences and honorarium from CSL Behring. | 06/06/2024 | It was agreed that Dr Kahn's declaration would not prevent her from providing expert advice to the committee. |
| Dr Charles Percy | Clinical expert | Direct – Financial | Dr Percy has received payment for attending advisory boards and for speaking at educational events from Takeda, Roche-Chugai, Sobi, LFB and Novo Nordisk. None of these are active conflicts at present. | 06/06/2024 | It was agreed that Dr Percy's declaration would not prevent her from providing expert advice to the committee. |